Sandra Robrecht

13PUBLICATIONS

60CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursInnate immunityMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 20, 2026

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

|Mar 30, 2026

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Mar 17, 2026

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Florian Simon, Rudy Ligtvoet, Moritz Fürstenau

|Feb 24, 2026

Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP.

Onur Cetin, Igor Kos, Evi Regitz

|Jan 13, 2026

The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

Othman Al-Sawaf, Benjamin N Locher, Friederike Christen

|Dec 08, 2025

Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP.

Onur Cetin, Igor Kos, Evi Regitz

Pageof 3

Frequent Collaborators

Michael J Hallek

Moritz Fürstenau

Florian Simon

Petra Langerbeins

Philipp B Staber

Rudy Ligtvoet

Julia von Tresckow

Carsten Utoft Niemann

3 joint publications

Othman Al-Sawaf

2 joint publications

Caspar da Cunha-Bang

Frequent Collaborators

Michael J Hallek

Moritz Fürstenau

Florian Simon

Petra Langerbeins